On October 22, the Jinfeng Laboratory, located in the High-tech Zone of Chongqing, held its annual technology achievement conference for 2024. The event showcased six innovative scientific results covering areas such as spatial multi-omics technology, intelligent computing platforms, artificial intelligence-based pathology diagnostics, and optimized drug design. Many of these original accomplishments are designed to support industrial development and clinical applications.
According to reports, the Jinfeng Laboratory was established as part of Chongqing’s strategy to implement the Chengdu-Chongqing economic circle, aiming to develop a nationally influential center for technological innovation. Since its inauguration in June 2022, the laboratory has focused on “next-generation diagnostics for major diseases” and has been accelerating its research platform development.
Among the releases this year is a next-generation sequencer jointly developed by the Jinfeng Laboratory’s Wang Zheng team and Shanghai Xinxiang Biotechnology Co., which utilizes high-throughput chip integration technology. This device is intended for early screening of major diseases such as tumors, prenatal testing, pathogen detection, and genetic disease testing. It effectively shortens the timeline for generating sequencing reports while enhancing accuracy and stability of analysis.
Luo Shaobo, Senior R&D Director at Shanghai Xinxiang Biotechnology, explained, “Traditionally, sequencing machines are developed based on specific throughput levels, requiring different devices to accommodate varying throughput needs. Our new sequencer can be customized according to throughput requirements, allowing one machine to cover a range of throughput levels needed for mainstream sequencing applications. This flexibility enables sequencing technology to better serve various applications, and we have applied for patents in China and overseas for the related technology.”
Luo further mentioned, “Currently, we have partnered with eight hospitals and institutions, including the Li Ka Shing Faculty of Medicine at the University of Hong Kong, the Center for Neurodegenerative Diseases in Hong Kong, and Singapore’s Genome Institute of Singapore, to conduct clinical applications together.”
In addition to the next-generation sequencer, the remaining five key technological achievements announced include: single-base precision 3D panoramic spatial multi-omics technology, a single-cell multi-omics intelligent computing platform, the first central nervous system methylation cluster map for the Chinese population, a full-parameter AI drug-likeness (ADMET) prediction platform, and an AI-assisted animal pathology system.
A representative from Jinfeng Laboratory stated that these projects, powered by artificial intelligence and big data, are accelerating the transition from “diagnosing diseases” to “computing diseases.”
